Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market
Subscribe To Our Newsletter & Stay Updated
